


### I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims:**

Claim 1 (withdrawn): A method for enhancing the radiosensitivity of a neoplastic cell comprising contacting the neoplastic cell with a radiosensitivity increasing amount of indolocarbazole derivative having the following structure A




wherein R<sub>1</sub> is not NCH<sub>3</sub> and wherein R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH.

Claim 2 (withdrawn): The method of claim 1, wherein R<sub>1</sub> is NH, O, or NOH.

Claim 3 (withdrawn): The method of claim 1, wherein R<sub>2</sub> and R<sub>3</sub> are Cl or H.

Claim 4 (withdrawn): The method of claim 1, wherein the amount of indolocarbazole derivative is at a non-cytotoxic level.

Claim 5 (withdrawn): A method for enhancing the radiosensitivity of a neoplastic cell comprising contacting the neoplastic cell with a radiosensitivity increasing amount of a composition comprising an indolocarbazole derivative having the following structure A



wherein R<sub>1</sub> is not NCH<sub>3</sub> and wherein R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH.

Claim 6 (withdrawn): The method of claim 5, wherein R<sub>1</sub> is NH, O, or NOH.

Claim 7 (withdrawn): The method of claim 5, wherein R<sub>2</sub> and R<sub>3</sub> are Cl or H.


Claim 8 (withdrawn): The method of claim 5, wherein the composition further comprises a pharmaceutically acceptable carrier.

Claim 9 (withdrawn): The method of claim 5, wherein the amount of composition is at a non-cytotoxic level.

Claim 10 (withdrawn) The method of claim 1, wherein the neoplastic cell is solid tumor cell or cancer cell.

Claim 11 (withdrawn): The method of claim 1, wherein the neoplastic cell is selected from the group consisting of prostate cancer cell, bone cancer cell, colon cancer cell, lymphoma cancer cell, and brain cancer cell.

Claim 12 (withdrawn): A method for treating a neoplastic cell comprising  
contacting the neoplastic cell with a radiosensitivity increasing amount of  
indolocarbazole derivative having the following structure A



wherein R<sub>1</sub> is not NCH<sub>3</sub> and wherein R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH; and

contacting the neoplastic cell with radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent.


Claim 13 (withdrawn): The method of claim 12, wherein R<sub>1</sub> is NH, O, or NOH.

Claim 14 (withdrawn): The method of claim 12, wherein R<sub>2</sub> and R<sub>3</sub> are Cl or H.

Claim 15 (withdrawn): The method of claim 12, wherein the neoplastic cell is contacted with the indolocarbazole derivative before being contacted with radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent.

Claim 16 (withdrawn): The method of claim 12, wherein the amount of indolocarbazole derivative is at a non-cytotoxic level.

Claim 17 (withdrawn): A method for treating a neoplastic cell comprising contacting the neoplastic cell with a radiosensitivity increasing amount of a composition comprising an indolocarbazole derivative having the following structure A



wherein R<sub>1</sub> is not NCH<sub>3</sub> and wherein R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH; and contacting the neoplastic cell with radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent.

Claim 18 (withdrawn): The method of claim 17, wherein R<sub>1</sub> is NH, O, or NOH.

Claim 19 (withdrawn): The method of claim 17, wherein R<sub>2</sub> and R<sub>3</sub> are Cl or H.


Claim 20 (withdrawn): The method of claim 17, wherein the composition further comprises a pharmaceutically acceptable carrier.

Claim 21 (withdrawn): The method of claim 17, wherein the amount of composition is at a non-cytotoxic level.

Claim 22 (withdrawn): The method of claim 17, wherein the neoplastic cell is contacted with the composition before being contacted with radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent.

Claim 23 (previously presented) A method for treating a neoplastic growth associated with tumor or cancer comprising

administering to a subject in need of such treatment radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent and a radiosensitivity increasing amount of an indolocarbazole derivative having the following structure A



wherein R<sub>1</sub> is not NCH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH, and wherein the amount of indolocarbazole derivative does not cause a substantial cytotoxic effect.

Claim 24 (original): The method of claim 23, wherein R<sub>1</sub> is NH, O, or NOH.


Claim 25 (original): The method of claim 23, wherein R<sub>2</sub> and R<sub>3</sub> are Cl or H.

Claim 26 (cancelled)

Claim 27 (original): The method of claim 23, wherein the indolocarbazole derivative is administered before the radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent.

Claim 28 (previously presented): A method for treating a neoplastic growth associated with tumor or cancer comprising

administering to a subject in need of such treatment radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent and a radiosensitivity increasing amount of a composition comprising an indolocarbazole derivative having the following structure A



wherein R<sub>1</sub> is not NCH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH, and wherein the amount of the composition does not cause a substantial cytotoxic effect.

Claim 29 (original): The method of claim 28, wherein R<sub>1</sub> is NH, O, or NOH.

Claim 30 (original): The method of claim 28, wherein R<sub>2</sub> and R<sub>3</sub> are Cl or H.

Claim 31 (cancelled)

Claim 32 (original): The method of claim 28, wherein the composition further comprises a pharmaceutically acceptable carrier.

Claim 33 (original): The method of claim 28, wherein the composition is administered before the radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent.

Claim 34 (cancelled)

Claim 35 (previously presented): The method of claim 23, wherein the neoplastic growth is in prostate, bone, colon, brain, lymphocyte, or breast.

Claim 36 (previously presented): The method of claim 23, wherein the neoplastic growth is in breast.


Claim 37 (cancelled)

Claim 38 (previously presented): The method of claim 28, wherein the neoplastic growth is in prostate, bone, colon, brain, lymphocyte, or breast.

Claim 39 (previously presented): The method of claim 28, wherein the neoplastic growth is in breast.

Claim 40 (new): A method for treating a subject in a condition associated with neoplastic cell comprising


administering to a subject in need of such treatment radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent and a radiosensitivity increasing amount of an indolocarbazole derivative having the following structure A



wherein R<sub>1</sub> is not NCH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH, and wherein the amount of indolocarbazole derivative does not cause a substantial cytotoxic effect.

Claim 41 (new): A method for treating a subject in a condition associated with neoplastic cell comprising

administering to a subject in need of such treatment radiation or radiation in combination with an anti-neoplastic chemotherapeutic agent and a radiosensitivity increasing amount of a composition comprising an indolocarbazole derivative having the following structure A



wherein R<sub>1</sub> is not NCH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are not H when R<sub>1</sub> is NH, and wherein the amount of the composition does not cause a substantial cytotoxic effect.